Study analysis · BMC Pregnancy and Childbirth · 2019
Omega-3 pills won't fix your pregnancy insulin resistance — but your weight might.
Taking fish oil pills during pregnancy doesn't help your body use sugar better, but if you had a higher weight before or gained a lot during pregnancy, your insulin resistance gets worse.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study didn't prove that taking fish oil makes pregnant women's bodies better at handling sugar. But it did find that women who naturally had more DHA (a type of fat in fish) in their blood also had better markers for how well their body used sugar. That doesn't mean the fish oil caused it — it just means the two things were linked.
What’s the bottom line?
Scientists gave pregnant women omega-3 fish oil pills to see if it helped their bodies use sugar better, but it didn't. Still, moms with more DHA (a type of omega-3) in their blood naturally had better sugar control.
How strong is this study?
This study was well-designed because it started as a real experiment where women were randomly assigned to take fish oil or a fake pill — that's the gold standard. But since they only looked at blood samples after the fact, we can't be totally sure if the DHA was the reason for the results. Still, it's one of the best kinds of studies we have.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
62 / 100
- Randomizationnot randomized
- Blinding+15/15
- Control group+15/15
- Sample size (n=126)+9.3/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design can establish causation. This study is a secondary analysis of a randomized controlled trial, so randomization establishes causal potential. However, the secondary analysis of biomarkers was not the primary outcome and may have reduced power, limiting confidence in causal claims for specific biomarkers like DHA and ALR.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and the study was funded by independent sources with no evidence of funder influence on design, analysis, or publication.
Funders
Independent Analysis Safeguards
- Double-blinded, randomized controlled trial design
- Analysis of de-identified samples approved by IRB
- Pre-registered trial (NCT00711971)
- Statistical analysis performed using standard, pre-specified methods
The study is a secondary analysis of a previously registered and IRB-approved trial. Funding sources are government institutions (NIH institutes), not industry. No author affiliations with industry or financial ties to supplement manufacturers are mentioned. No evidence of funder influence on outcomes or publication.
Key takeaways
- 01
Fish oil pills: no change in sugar control markers.
- 02
Higher mom's DHA: 1% increase linked to higher sugar-control ratio (ALR).
- 03
Higher cord DHA: linked to higher leptin (a hormone).
- 04
Higher mom's BMI or weight gain: strongly linked to worse sugar control.
- 05
The DHA-insulin link is real but not caused by pills — it's a natural association.
- 06
Weight gain and pre-pregnancy weight had bigger effects than omega-3 levels.
Surprising findings
- Cord blood DHA was linked to higher cord leptin, not better insulin sensitivity.Leptin is usually a marker of fat mass and insulin resistance — so higher cord DHA leading to higher leptin suggests a potential link to fetal fat storage or future obesity risk, not protection.
- Vitamin D was linked to higher adiponectin at enrollment, but not after supplementation.While not the focus, this hints that vitamin D might play a role in early insulin sensitivity — a hidden variable most people overlook.
Practical takeaways
Focus on managing pre-pregnancy BMI and avoiding excessive weight gain during pregnancy to protect insulin sensitivity.
This study only looked at women at risk for depression — results may not apply to all pregnant women, and insulin sensitivity was measured via proxy (ALR), not HOMA-IR.
medium confidenceWhy this study matters
Fish Oil Doesn't Boost Insulin Sensitivity
Despite randomizing 126 pregnant women to EPA-rich, DHA-rich, or placebo fish oil, the study found no significant difference in adiponectin, leptin, or the adiponectin:leptin ratio (ALR) — a key marker of insulin sensitivity — between any groups at baseline, after supplementation, or in cord blood.
Millions of pregnant women take omega-3 supplements hoping to improve metabolic health — but this study shows they're not helping with insulin sensitivity, even though the trial was well-designed and double-blinded.
Natural DHA ≠ Supplemental DHA
Higher natural levels of maternal serum DHA (not from supplements) were linked to a higher ALR — meaning better insulin sensitivity — both before (p=0.01) and after (p=0.04) supplementation. This suggests DHA’s benefit comes from diet or metabolism, not pills.
It flips the script: it’s not the supplement that helps, but your body’s natural DHA levels. This could mean food sources or genetics matter more than pills.
Weight Gain Is the Real Villain
Pre-pregnancy BMI had a strong inverse link to ALR (p<0.001), and pregnancy weight gain was also significantly linked to worse insulin sensitivity (p<0.02). The ALR dropped 31% from early to late pregnancy — a massive metabolic shift.
This is the most powerful finding: your weight before and during pregnancy matters far more than any supplement. It shifts focus from pills to lifestyle.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave pregnant women omega-3 fish oil pills to see if it helped their bodies use sugar better, but it didn't. Still, moms with more DHA (a type of omega-3) in their blood naturally had better sugar control.
Research results
Fish oil pills: no change in sugar control markers. Higher mom's DHA: 1% increase linked to higher sugar-control ratio (ALR). Higher cord DHA: linked to higher leptin (a hormone). Higher mom's BMI or weight gain: strongly linked to worse sugar control.
What this means - more context
The DHA-insulin link is real but not caused by pills — it's a natural association. Weight gain and pre-pregnancy weight had bigger effects than omega-3 levels.
This study investigated whether prenatal EPA or DHA supplementation improves maternal and cord blood markers of insulin sensitivity, using a secondary analysis of a randomized trial.
Prenatal EPA or DHA supplementation showed no significant effect on maternal or cord blood adiponectin, leptin, or adiponectin:leptin ratio (ALR). However, higher maternal serum DHA fraction was associated with increased ALR, and cord DHA was linked to higher cord leptin. Higher pre-pregnancy BMI and pregnancy weight gain were strongly associated with reduced insulin sensitivity.
Methods Used
Secondary analysis of 126 pregnant women randomized to EPA-rich, DHA-rich, or placebo fish oil in a double-blind trial. Maternal blood was collected at 12–20 and 34–36 weeks; cord blood at delivery. Adiponectin and leptin were measured via ELISA to calculate ALR. Multivariable linear regression assessed associations between fatty acid fractions, BMI, weight gain, and insulin markers.
Main Finding
EPA and DHA supplementation had no effect on insulin sensitivity markers (ALR, adiponectin, leptin) in maternal or cord blood. Maternal DHA fraction was positively associated with ALR (p=0.01 pre-supplementation, p=0.04 post-supplementation). Cord DHA was associated with higher cord leptin (p=0.02). Higher pre-pregnancy BMI and weight gain were strongly inversely associated with ALR (p<0.001 and p<0.02, respectively).
Confidence Level
Moderate. The study is a well-conducted secondary analysis of a double-blind RCT with strong biomarker measurement precision (low CVs). However, sample size was powered for depression outcomes, not insulin markers, and the cohort was selected for depression risk, limiting generalizability.
Study Flags
Red Flags
- •Secondary analysis of a trial not powered for this outcome
- •Cohort selected for depression risk, not general pregnancy population
- •No confidence intervals reported for effect sizes
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Cord blood DHA was linked to higher cord leptin, not better insulin sensitivity.
Leptin is usually a marker of fat mass and insulin resistance — so higher cord DHA leading to higher leptin suggests a potential link to fetal fat storage or future obesity risk, not protection.
Practical Takeaways
Focus on managing pre-pregnancy BMI and avoiding excessive weight gain during pregnancy to protect insulin sensitivity.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study didn't prove that taking fish oil makes pregnant women's bodies better at handling sugar. But it did find that women who naturally had more DHA (a type of fat in fish) in their blood also had better markers for how well their body used sugar. That doesn't mean the fish oil caused it — it just means the two things were linked.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Original study was a double-blinded, randomized controlled trial
- Use of pre-existing, well-characterized samples with baseline and follow-up measurements
- Adjustment for key confounders (BMI, age, weight gain) in regression models
Weaknesses
- Secondary analysis not pre-specified in original protocol
- Reduced statistical power for secondary outcomes
- Sample not representative of general pregnant population
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave pregnant women omega-3 fish oil pills to see if it helped their bodies use sugar better, but it didn't. Still, moms with more DHA (a type of omega-3) in their blood naturally had better sugar control.
Research results
Fish oil pills: no change in sugar control markers. Higher mom's DHA: 1% increase linked to higher sugar-control ratio (ALR). Higher cord DHA: linked to higher leptin (a hormone). Higher mom's BMI or weight gain: strongly linked to worse sugar control.
What this means - more context
The DHA-insulin link is real but not caused by pills — it's a natural association. Weight gain and pre-pregnancy weight had bigger effects than omega-3 levels.
This study investigated whether prenatal EPA or DHA supplementation improves maternal and cord blood markers of insulin sensitivity, using a secondary analysis of a randomized trial.
Prenatal EPA or DHA supplementation showed no significant effect on maternal or cord blood adiponectin, leptin, or adiponectin:leptin ratio (ALR). However, higher maternal serum DHA fraction was associated with increased ALR, and cord DHA was linked to higher cord leptin. Higher pre-pregnancy BMI and pregnancy weight gain were strongly associated with reduced insulin sensitivity.
Methods Used
Secondary analysis of 126 pregnant women randomized to EPA-rich, DHA-rich, or placebo fish oil in a double-blind trial. Maternal blood was collected at 12–20 and 34–36 weeks; cord blood at delivery. Adiponectin and leptin were measured via ELISA to calculate ALR. Multivariable linear regression assessed associations between fatty acid fractions, BMI, weight gain, and insulin markers.
Main Finding
EPA and DHA supplementation had no effect on insulin sensitivity markers (ALR, adiponectin, leptin) in maternal or cord blood. Maternal DHA fraction was positively associated with ALR (p=0.01 pre-supplementation, p=0.04 post-supplementation). Cord DHA was associated with higher cord leptin (p=0.02). Higher pre-pregnancy BMI and weight gain were strongly inversely associated with ALR (p<0.001 and p<0.02, respectively).
Confidence Level
Moderate. The study is a well-conducted secondary analysis of a double-blind RCT with strong biomarker measurement precision (low CVs). However, sample size was powered for depression outcomes, not insulin markers, and the cohort was selected for depression risk, limiting generalizability.
Study Flags
Red Flags
- •Secondary analysis of a trial not powered for this outcome
- •Cohort selected for depression risk, not general pregnancy population
- •No confidence intervals reported for effect sizes
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Cord blood DHA was linked to higher cord leptin, not better insulin sensitivity.
Leptin is usually a marker of fat mass and insulin resistance — so higher cord DHA leading to higher leptin suggests a potential link to fetal fat storage or future obesity risk, not protection.
Practical Takeaways
Focus on managing pre-pregnancy BMI and avoiding excessive weight gain during pregnancy to protect insulin sensitivity.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study didn't prove that taking fish oil makes pregnant women's bodies better at handling sugar. But it did find that women who naturally had more DHA (a type of fat in fish) in their blood also had better markers for how well their body used sugar. That doesn't mean the fish oil caused it — it just means the two things were linked.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Original study was a double-blinded, randomized controlled trial
- Use of pre-existing, well-characterized samples with baseline and follow-up measurements
- Adjustment for key confounders (BMI, age, weight gain) in regression models
Weaknesses
- Secondary analysis not pre-specified in original protocol
- Reduced statistical power for secondary outcomes
- Sample not representative of general pregnant population
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was well-designed because it started as a real experiment where women were randomly assigned to take fish oil or a fake pill — that's the gold standard. But since they only looked at blood samples after the fact, we can't be totally sure if the DHA was the reason for the results. Still, it's one of the best kinds of studies we have.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
62 / 100
- Randomizationnot randomized
- Blinding+15/15
- Control group+15/15
- Sample size (n=126)+9.3/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design can establish causation. This study is a secondary analysis of a randomized controlled trial, so randomization establishes causal potential. However, the secondary analysis of biomarkers was not the primary outcome and may have reduced power, limiting confidence in causal claims for specific biomarkers like DHA and ALR.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and the study was funded by independent sources with no evidence of funder influence on design, analysis, or publication.
Funders
Independent Analysis Safeguards
- Double-blinded, randomized controlled trial design
- Analysis of de-identified samples approved by IRB
- Pre-registered trial (NCT00711971)
- Statistical analysis performed using standard, pre-specified methods
The study is a secondary analysis of a previously registered and IRB-approved trial. Funding sources are government institutions (NIH institutes), not industry. No author affiliations with industry or financial ties to supplement manufacturers are mentioned. No evidence of funder influence on outcomes or publication.